Table 1 Baseline characteristics of cirrhotic patients with and without HCC
From: VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma
Variable | Total (n = 61) | Patients with HCC (n = 41) | Patients without HCC (n = 20) | P value |
|---|---|---|---|---|
Age (years) | 74 (67–79) | 78 (67–79) | 72 (64–76) | 0.19 |
Sex (male/female) | 42/19 | 32/9 | 10/10 | 0.04 |
HCV/HBV/Alcohol/NASH/AIH | 28/16/8/6/3 | 17/11/6/6/1 | 11/5/2/0/2 | 0.26 |
Albumin (g/dL) | 4.1 (3.6–4.4) | 3.9 (3.4–4.1) | 4.4 (4.2–4.6) | 0.000004 |
Total bilirubin (mg/dL) | 0.9 (0.7–1.2) | 0.9 (0.7–1.2) | 0.85 (0.8–1.2) | 0.88 |
Aspartate aminotransferase (IU/L) | 30 (22–41) | 30 (21–47) | 29.5 (26–34) | 0.68 |
Alanine aminotransferase (IU/L) | 27 (19–47) | 33 (21–47) | 22 (16–36) | 0.12 |
alkaline phosphatase (IU/L) | 315 (233–432) | 315 (237–427) | 314 (230–483) | 0.93 |
γ-glutamyl transpeptidase (IU/L) | 33 (24–56) | 32 (24–82) | 34 (23–45) | 0.58 |
Prothrombin time (%) | 78 (69–87) | 75 (70–84) | 81 (75–85) | 0.21 |
Child-Pugh score | 5.0 (5–6) | 5.0 (5–6) | 5.0 (5–5) | 0.058 |
Platelet count (×104/μL) | 11.9 (9.0–14.8) | 11.9 (9.1–15.4) | 11.2 (9.0–13.0) | 0.52 |
Tumor size (cm) |  | 1.6 (1.2–2.2) |  | |
Tumor volume (cm3) | 4.0 (1.7–6.1) | |||
UICC TNM stage (stage 1/stage 2/stage 3) | 15/19/7 | |||
GALAD model (Score, Probability) | 1.8 (0.7–3.2), 85 (66–96) | 2.4 (1.5–3.4), 92 (81–98) | 0.7 (−1.1–1.1), 67 (27–75) | 0.00056, 0.00068 |